David E. Anderson, VBI’s Chief Scientific Officer: "VBI-2902 has the potential to offer substantial benefit in the prevention of COVID-19, including robust immunogenicity at fewer doses without the need for transportation in ultra-cold chains. Based on the strength of this preclinical data, we initiated a Phase 1/2 study in Canada in adults and look forward to sharing initial data by the end of the second quarter of 2021."
https://finance.yahoo.com/news/vbi-vaccines-announces-publication-preclinical-120000959.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.